Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor

Journal of Medicinal Chemistry

Volumn 40, Issue 6, 1997, Pages 898-902

  Bäckbro, Kristina ^a   Löwgren, Seved ^a   Österlund, Katrin ^a   Atepo, Johnson ^a   Unge, Torsten ^a   Hultén, Johan ^a   Bonham, Nicholas M ^a   Schaal, Wesley ^a   Karlén, Anders ^a   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; SULFANILAMIDE; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

AZEPINES; BINDING SITES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN BINDING; SULFONAMIDES;

EID: 0043222419     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960588d     Document Type: Article

References (43)

1. Barré-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220, 868-871.
2. Gallo, R. C.; Sarin, P. S.; Gelmann, E. P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V. S.; Mann, D.; Sidhu, G. D.; Stahl, R. E.; Zolla-Pazner, S.; Leibowitch, J.; Popovic, M. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983, 220, 865-867.
3. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
4. Debouck, C.; Metcalf, B. W. Human immunodeficiency virus protease: A target for AIDS therapy. Drug Dev. Res. 1990, 21, 1-17.
5. Debouck, C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Human Retroviruses 1992, 8, 153-164.
6. Huff, J. R. HIV protease: A novel chemotherapeutic target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
7. Tomasselli, A. G.; Howe, W. J.; Sawyer, T. K.; Wlodawer, A.; Heinrikson, R. L. The complexities of AIDS: An assesment of the HIV protease as a therapeutic target. Chimicaoggi 1991, 9, 6-27.
8. Pearl, L. H.; Taylor, W. R. A structural model for the retroviral protease. Nature 1987, 329, 351-354.
9. Miller, M.; Jaskólski, M.; Rao, J. K. M.; Leis, J.; Wlodawer, A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 1989, 337, 576-579.
10. Navia, M. A.; Fitzgerald, P. M. D.; McKeever, B. M.; Leu, C. T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989, 337, 615-620.
11. Wlodawer, A.; Miller, M.; Jaskolski, M.; Sathyanarayana, B. K.; Baldwin, I.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schneider, J.; Kent, S. B. H. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 1989, 245, 616-621.
12. Lapatto, R.; Blundell, T.; Hemmings, A.; Overington, J.; Wilderspin, A.; Wood, S.; Merson, J. R.; Whittle, P. J.; Danley, D. E.; Geoghegan, K. F.; Hawrylik, S. J.; Lee, S. E.; Scheid, K. G.; Hobart, P. M. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 1989, 342, 299-302.
13. West, M. L.; Fairlie, D. P. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75.
14. Miller, M.; Schneider, J.; Sathyanarayana, B. K.; Toth, M. V.; Marshall, G. R.; Clawson, L.; Selk, L.; Kent, S. B. H.; Wlodawer, A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science 1989, 246, 1149-1152.
15. Cooper, J. B.; Foundling, S. I.; Blundell, T. L.; Boger, J.; Jupp, R. A.; Kay, J. X-ray studies of aspartic proteinase-statine compexes. Biochemistry 1989, 28, 8596-8603.
16. Fitzgerald, P. M. D.; McKeever, B. M.; VanMiddlesworth, J. F.; Springer, J. P.; Heimbach, J. C.; Leu, C.-T.; Herber, W. K.; Dixon, R. A. P.; Darke, P. L. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin a 2.0 Å resolution. J. Biol. Chem. 1990, 265, 14209-14219.
17. Swain, A. L.; Miller, M. M.; Green, J.; Rich, D. H.; Schneider, J.; Kent, S. B. H.; Wlodawer, A. X-ray Crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 8805-8809.
18. 2 symmetric inhibitor complexed to HIV-1 protease. Science 1990, 249, 527-533.
19. Jaskólski, M.; Tomasselli, A. G.; Sawyer, T. K.; Staples, D. G.; Heinrikson, R. L.; Schneider, J.; Kent, S. B. H.; Wlodawer, A. Structure at 2.5 Å resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydrocyethylene-based inhibitor. Biochemistry 1991, 30, 1600-1609.
20. 2 symmetry. J. Am. Chem. Soc. 1991, 113, 9382-9384.
21. Appell, K. Crystal structures of HIV-1 protease-inhibitor complexes. Perspect. Drug Dis. Des. 1993, 1, 23-48.
22. Wlodawer, A.; Erickson, J. W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 1993, 62, 543-585.
23. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Kayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 1994, 263, 380-384.
24. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; DeLucca, G. V.; Rodgers, J. D. WO9419329-A 94.09.01.
25. Hultén, J.; Bonham, N. M.; Nillroth, U.; Hansson, T.; Zuccarello, G.; Bouzide, A.; Åqvist, J.; Classon, B.; Danielson, H.; Karlén, A.; Kvarnström, I.; Samuelsson, B.; Hallberg, A. Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding affinities. J. Med. Chem. 1997, 40, 885-897.
26. Erickson, J. W. Design and structure of symmetry-based inhibitors of HIV-1 protease. Perspect. Drug Dis. Des. 1993, 1, 109-128.
27. 2 symmetry-based diol inhibitors of HIV-1 protease. J. Am. Chem. Soc. 1994, 116, 847-855.
28. Vara Prasad, J. V. N.; Pavlovsky, A.; Para, K. S.; Ellsworth, E. L.; Tummino, P. J.; Nouhan, C.; Ferguson, D. Nonpeptidic HIV protease inhibitors: 3-(S-benzylsubstituted)-4-hydroxy-6-(phenyl substituted)-2H-pyran-2-one with an inverse mode of binding. Bioorg. Med. Chem. Lett. 1996, 6, 1133-1138.
29. Reich, S. H.; Melnick, M.; Davies, J. F., II; Appelt, K.; Lewis, K. K.; Fuhry, M. A.; Pino, M.; Trippe, A. J.; Nguyen, D.; Dawson, H.; Wu, B. W.; Musick, L.; Kosa, M.; Kahil D.; Webber, S.; Gehlhaar, D. K.; Andrada, D.; Shetty, B. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3298-3302.
30. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F., Jr.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: A computer based archival file for macromolecular structures. J. Mol. Biol. 1977, 112, 535-542.
31. Silva, A. M.; Cachau, R. E.; Sham, H. L.; Erickson, J. W. Inhibition and catalytic mechanism of HIV-1 aspartic protease. J. Mol. Biol. 1996, 255, 321-340.
32. Allen, F. H.; Kennard, O. 3D search and research using the Cambridge Structural Database. Chem. Des. Automation News 1993, 8, 31-37.
33. Lee, C.-H.; Kohn, H. Intra- and intermolecular α-sulfamidoalkylation reactions. J. Org. Chem. 1990, 55, 6098-6104.
34. Bäckbro, K.; Zhang, H.; Vrang, L.; Öberg, B.; Unge, T. Unpublished results.
35. Taylor, A.; Brown, D. P.; Kadam, S.; Maus, M.; Kohlbrenner, W. E.; Weigl, D.; Turon, M. C.; Katz, L. High-level expression and purification of mature HlV-1 protease in Escherichia coli under control of the araBAD promoter. Appl. Microbiol. Biotechnol. 1992, 37, 205-210.
36. Otwinowski, Z.; Minor, W. The HKL Program Suite.
37. Gewirth, D.; Otwinowski, Z. The SCALEPACK Manual: 1995.
38. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
39. Brünger, A. T.; Kuriyan, J.; Karplus, M. Cristallographic R factor refinement by molecular dynamics. Science 1987, 235, 458-460.
40. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in election density maps and the location of errors in these models. Acta Crystallogr. A 1991, 47, 110-119.
41. Brünger, A. T. The free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355, 472-474.
42. Engh, R. A.; Huber, R. Accurate bond and angle parameters for X-ray protein structure refinement. Ada Crystallogr. A 1991, 47, 392-400.
43. Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.